{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:59:55Z","timestamp":1771653595919,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T00:00:00Z","timestamp":1265241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00428-010-0881-0","type":"journal-article","created":{"date-parts":[[2010,2,3]],"date-time":"2010-02-03T08:37:50Z","timestamp":1265186270000},"page":"235-243","source":"Crossref","is-referenced-by-count":30,"title":["PIKing the right isoform: the emergent role of the p110\u03b2 subunit in breast cancer"],"prefix":"10.1007","volume":"456","author":[{"given":"Silvia","family":"Carvalho","sequence":"first","affiliation":[]},{"given":"Fernanda","family":"Milanezi","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Amendoeira","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,2,4]]},"reference":[{"key":"881_CR1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606\u2013619","journal-title":"Nat Rev Genet"},{"key":"881_CR2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655\u20131657","journal-title":"Science"},{"key":"881_CR3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0165-6147(03)00163-9","volume":"24","author":"MP Wymann","year":"2003","unstructured":"Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signalling\u2013which way to target. Trends Pharmacol Sci 24:366\u2013376","journal-title":"Trends Pharmacol Sci"},{"key":"881_CR4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nrc1753","volume":"5","author":"AG Bader","year":"2005","unstructured":"Bader AG, Kang S, Zhao L et al (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5:921\u2013929","journal-title":"Nat Rev Cancer"},{"key":"881_CR5","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497\u20135510","journal-title":"Oncogene"},{"key":"881_CR6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550\u2013562","journal-title":"Nat Rev Cancer"},{"key":"881_CR7","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.ejca.2008.09.026","volume":"44","author":"S Cosimo Di","year":"2008","unstructured":"Di Cosimo S, Baselga J (2008) Targeted therapies in breast cancer: where are we now. Eur J Cancer 44:2781\u20132790","journal-title":"Eur J Cancer"},{"key":"881_CR8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ceb.2008.12.006","volume":"21","author":"S Klein","year":"2009","unstructured":"Klein S, Levitzki A (2009) Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 21:185\u2013193","journal-title":"Curr Opin Cell Biol"},{"key":"881_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/5042","volume":"21","author":"L Shayesteh","year":"1999","unstructured":"Shayesteh L, Lu Y, Kuo WL et al (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99\u2013102","journal-title":"Nat Genet"},{"key":"881_CR10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0959-8049(98)00419-5","volume":"35","author":"A Racz","year":"1999","unstructured":"Racz A, Brass N, Heckel D et al (1999) Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma. Eur J Cancer 35:641\u2013646","journal-title":"Eur J Cancer"},{"key":"881_CR11","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1158\/0008-5472.CAN-08-4450","volume":"69","author":"RJ Crowder","year":"2009","unstructured":"Crowder RJ, Phommaly C, Tao Y et al (2009) PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69:3955\u20133962","journal-title":"Cancer Res"},{"key":"881_CR12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","volume":"18","author":"Y Samuels","year":"2006","unstructured":"Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77\u201382","journal-title":"Curr Opin Oncol"},{"key":"881_CR13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","volume":"6","author":"M Cully","year":"2006","unstructured":"Cully M, You H, Levine AJ et al (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184\u2013192","journal-title":"Nat Rev Cancer"},{"key":"881_CR14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489\u2013501","journal-title":"Nat Rev Cancer"},{"key":"881_CR15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ceb.2005.02.011","volume":"17","author":"MP Wymann","year":"2005","unstructured":"Wymann MP, Marone R (2005) Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 17:141\u2013149","journal-title":"Curr Opin Cell Biol"},{"key":"881_CR16","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2008.246","volume":"27","author":"C Garcia-Echeverria","year":"2008","unstructured":"Garcia-Echeverria C, Sellers WR (2008) Drug discovery approaches targeting the PI3K\/Akt pathway in cancer. Oncogene 27:5511\u20135526","journal-title":"Oncogene"},{"key":"881_CR17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjc.6602970","volume":"94","author":"B Karakas","year":"2006","unstructured":"Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94:455\u2013459","journal-title":"Br J Cancer"},{"key":"881_CR18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00428-008-0643-4","volume":"453","author":"E Lerma","year":"2008","unstructured":"Lerma E, Catasus L, Gallardo A et al (2008) Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch 453:133\u2013139","journal-title":"Virchows Arch"},{"key":"881_CR19","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","volume":"65","author":"LH Saal","year":"2005","unstructured":"Saal LH, Holm K, Maurer M et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554\u20132559","journal-title":"Cancer Res"},{"key":"881_CR20","doi-asserted-by":"crossref","first-page":"18443","DOI":"10.1073\/pnas.0508988102","volume":"102","author":"JJ Zhao","year":"2005","unstructured":"Zhao JJ, Liu Z, Wang L et al (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 102:18443\u201318448","journal-title":"Proc Natl Acad Sci U S A"},{"key":"881_CR21","doi-asserted-by":"crossref","first-page":"ra3","DOI":"10.1126\/scisignal.1161577","volume":"1","author":"E Ciraolo","year":"2008","unstructured":"Ciraolo E, Iezzi M, Marone R et al (2008) Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 1:ra3","journal-title":"Sci Signal"},{"key":"881_CR22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","volume":"454","author":"S Jia","year":"2008","unstructured":"Jia S, Liu Z, Zhang S et al (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776\u2013779","journal-title":"Nature"},{"key":"881_CR23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","volume":"1784","author":"R Marone","year":"2008","unstructured":"Marone R, Cmiljanovic V, Giese B et al (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 1784:159\u2013185","journal-title":"Biochim Biophys Acta"},{"key":"881_CR24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s00428-005-0010-7","volume":"447","author":"I Matos","year":"2005","unstructured":"Matos I, Dufloth R, Alvarenga M et al (2005) p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447:688\u2013694","journal-title":"Virchows Arch"},{"key":"881_CR25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00428-006-0334-y","volume":"450","author":"J Paredes","year":"2007","unstructured":"Paredes J, Lopes N, Milanezi F et al (2007) P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 450:73\u201380","journal-title":"Virchows Arch"},{"key":"881_CR26","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","volume":"64","author":"IG Campbell","year":"2004","unstructured":"Campbell IG, Russell SE, Choong DY et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678\u20137681","journal-title":"Cancer Res"},{"key":"881_CR27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4161\/cbt.3.8.994","volume":"3","author":"KE Bachman","year":"2004","unstructured":"Bachman KE, Argani P, Samuels Y et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772\u2013775","journal-title":"Cancer Biol Ther"},{"key":"881_CR28","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","volume":"27","author":"L Zhao","year":"2008","unstructured":"Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486\u20135496","journal-title":"Oncogene"},{"key":"881_CR29","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1073\/pnas.0510772103","volume":"103","author":"S Kang","year":"2006","unstructured":"Kang S, Denley A, Vanhaesebroeck B et al (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 103:1289\u20131294","journal-title":"Proc Natl Acad Sci U S A"},{"key":"881_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.virol.2005.09.027","volume":"344","author":"PK Vogt","year":"2006","unstructured":"Vogt PK, Bader AG, Kang S (2006) Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Virology 344:131\u2013138","journal-title":"Virology"},{"key":"881_CR31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341\u2013354","journal-title":"Nat Rev Cancer"},{"key":"881_CR32","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-09-0632","volume":"15","author":"K Kalinsky","year":"2009","unstructured":"Kalinsky K, Jacks LM, Heguy A et al (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15:5049\u20135059","journal-title":"Clin Cancer Res"},{"key":"881_CR33","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","volume":"4","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Smith DL, Ram PT et al (2005) Exploiting the PI3K\/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988\u20131004","journal-title":"Nat Rev Drug Discov"},{"key":"881_CR34","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.0802655105","volume":"105","author":"S Wee","year":"2008","unstructured":"Wee S, Wiederschain D, Maira SM et al (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 105:13057\u201313062","journal-title":"Proc Natl Acad Sci U S A"},{"key":"881_CR35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/path.1829","volume":"207","author":"T Kirkegaard","year":"2005","unstructured":"Kirkegaard T, Witton CJ, McGlynn LM et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139\u2013146","journal-title":"J Pathol"},{"key":"881_CR36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-06-0267","volume":"13","author":"N Maruyama","year":"2007","unstructured":"Maruyama N, Miyoshi Y, Taguchi T et al (2007) Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13:408\u2013414","journal-title":"Clin Cancer Res"},{"key":"881_CR37","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J, Semiglazov V, van Dam P et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630\u20132637","journal-title":"J Clin Oncol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-010-0881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-010-0881-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-010-0881-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:35:56Z","timestamp":1559079356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-010-0881-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,4]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s00428-010-0881-0","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,4]]}}}